9 unchanged sentences
S-1/A 1/21/20 4.2
+Added: 10.1† Share Purchase Agreement, dated September 7, 2022, by and among the Registrant, Ducentis Biotherapeutics LTD and the certain stockholders of Ducentis Biotherapeutics LTD.
+Added: 10.2† Amendment No.
+Added: 1, dated October 5, 2022, to the Supply Agreement, dated November 24, 2020, by and among the Registrant and Interquim, S.A.
31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
10 unchanged sentences
______________
−Removed: † Registrant has omitted portions of the exhibit as permitted under Item 601(b)(10) of Regulation S-K.
+Added: † Registrant has omitted portions of the exhibit as permitted under Item 601(b)(10) of Regulation S-K, and certain of the exhibits and schedules to this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K.
+Added: The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.
* The certifications attached as Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of Arcutis Biopharmaceuticals, Inc.
2 unchanged sentences
ARCUTIS BIOTHERAPEUTICS, INC.
−Removed: August 04, 2022 By:
+Added: November 08, 2022 By:
/s/ Todd Franklin Watanabe
2 unchanged sentences
(Principal Executive Officer)
−Removed: August 04, 2022 By:
+Added: November 08, 2022 By:
Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.